AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22205309 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (RW) with 30 g alcohol/d
Number of subjects: 67
Study 22205309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine (DRW)
Number of subjects: 67
Study 22205309 — intervention group
Group type: EXPERIMENTAL
Intervention: Gin with 30 g alcohol/d
Number of subjects: 67
Study 22205309 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (from RW and gin)
Number of subjects: 67
Study 20550748 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk product
Number of subjects: 0
Study 20550748 — intervention group
Group type: COMPARATOR
Intervention: Conventional yoghurt
Number of subjects: 0
Study 20550748 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 0
Study 20550748 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus delbrueckii
Number of subjects: 0
Study 18176337 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate extended-release (D-MPH-ER) 20 mg/day
Number of subjects: 68
Study 18176337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 15792207 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty (Group A)
Number of subjects: 122
Study 15792207 — intervention group
Group type: COMPARATOR
Intervention: Dynamic screw fixation (Group B)
Number of subjects: 122
Study 15792207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study 12028210 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning bright light
Number of subjects: 77
Study 12028210 — intervention group
Group type: COMPARATOR
Intervention: Evening bright light
Number of subjects: 77
Study 12028210 — intervention group
Group type: COMPARATOR
Intervention: Daytime sleep restriction
Number of subjects: 77
Study 12028210 — intervention group
Group type: COMPARATOR
Intervention: Evening dim red light
Number of subjects: 77
Study 10339734 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily
Number of subjects: 20
Study 7564470 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan plus continuous oral vitamin A
Number of subjects: 153
Study 7564470 — intervention group
Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 153
Study 1948817 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine chloride 80 mg
Number of subjects: 24
Study 1948817 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine chloride 100 mg
Number of subjects: 24
Study 1948817 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine chloride 20-100 mg
Number of subjects: 24
Study 1948817 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine chloride 60-100 mg
Number of subjects: 24
Study 1948817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6119712 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic therapy with constant doses of butyrophenones
Number of subjects: 33
Study 30885522 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency pulsed electromagnetic field (PEMF)
Number of subjects: 0
Study 30885522 — intervention group
Group type: COMPARATOR
Intervention: Non-PEMF (NPEMF)
Number of subjects: 0
Study 29714073 — intervention group
Group type: EXPERIMENTAL
Intervention: All-polyethylene tibial component
Number of subjects: 59
Study 29714073 — intervention group
Group type: COMPARATOR
Intervention: Metal-backed tibial component
Number of subjects: 59
Study 27636018 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 (4 μg/kg/h) infusion
Number of subjects: 10
Study 27636018 — intervention group
Group type: COMPARATOR
Intervention: NK3R antagonist AZD4901 40 mg twice daily orally
Number of subjects: 10
Study 27636018 — intervention group
Group type: COMPARATOR
Intervention: NK3R antagonist AZD4901
Number of subjects: 10
Study 24831288 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lifestyle intervention (zhiji management) for 3 months
Number of subjects: 273
Study 24831288 — intervention group
Group type: COMPARATOR
Intervention: Late group (control phase)
Number of subjects: 273
Study 22307881 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 85
Study 22307881 — intervention group
Group type: COMPARATOR
Intervention: Veterans Health Administration Vocational Rehabilitation Program (VRP)
Number of subjects: 85
Study 22307881 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 85
Study 22307881 — intervention group
Group type: COMPARATOR
Intervention: VRP
Number of subjects: 85
Study 20621262 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized tailored physical activity reports
Number of subjects: 394
Study 20621262 — intervention group
Group type: COMPARATOR
Intervention: General reports on preventive screening
Number of subjects: 394
Study 17940786 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal infiltration with 2 mg/kg tramadol in 3 ml of normal saline (1.5 ml per tonsil)
Number of subjects: 40
Study 17940786 — intervention group
Group type: COMPARATOR
Intervention: Normal saline only (placebo)
Number of subjects: 40
Study 15965309 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg administered 4 times during the day with controlled-release levodopa/carbidopa 100 mg/25 mg (Sinemet CR)
Number of subjects: 16
Study 15965309 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg
Number of subjects: 16
Study 15965309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12798612 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCK cell grown influenza vaccine
Number of subjects: 48
Study 12798612 — intervention group
Group type: COMPARATOR
Intervention: Egg-derived influenza vaccine
Number of subjects: 48
Study 10822319 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4-8 mg/daily
Number of subjects: 191
Study 10822319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 8861091 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG mapping in depressed patients (Group C)
Number of subjects: 129
Study 8861091 — intervention group
Group type: COMPARATOR
Intervention: EEG mapping in menopausal syndrome patients without depression (Group A and B)
Number of subjects: 129
Study 8861091 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of estradiol levels with EEG measures
Number of subjects: 129
Study 8861091 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of EEG measures with Hamilton depression score (HAMD)
Number of subjects: 129
Study 8861091 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal asymmetry index in depressed patients (Group C)
Number of subjects: 129
Study 8861091 — intervention group
Group type: COMPARATOR
Intervention: Frontal asymmetry index in normal controls
Number of subjects: 129
Study 8861091 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of frontal asymmetry index with Hamilton depression score
Number of subjects: 129
Study 1513922 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.5 to 3.5 mg/day)
Number of subjects: 12
Study 1513922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6381081 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (postural drainage and periodic application of a face mask with positive expiratory pressure)
Number of subjects: 14
Study 6381081 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C (PEP in the sitting position)
Number of subjects: 14
Study 6381081 — intervention group
Group type: COMPARATOR
Intervention: Treatment A (postural drainage, percussion and vibration)
Number of subjects: 14
Study 6381081 — intervention group
Group type: COMPARATOR
Intervention: Treatment D (forced expiration technique in the sitting position)
Number of subjects: 14
Study 30586729 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (10 months of training followed by 14 months of maintenance exercise)
Number of subjects: 61
Study 30586729 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training
Number of subjects: 61
Study 30586729 — intervention group
Group type: COMPARATOR
Intervention: Stretching/balance control
Number of subjects: 61
Study 27288691 — intervention group
Group type: EXPERIMENTAL
Intervention: Encuentro program
Number of subjects: 49
Study 27288691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 27049053 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial preparation (2 × 250 mg)
Number of subjects: 20
Study 27049053 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (2 × 250 mg)
Number of subjects: 20
Study 27049053 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial preparation and Reference preparation
Number of subjects: 20
Study 24692001 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestroke statin use (n=51)
Number of subjects: 100
Study 24692001 — intervention group
Group type: COMPARATOR
Intervention: Prestroke nonstatin use (n=30)
Number of subjects: 100
Study 23091148 — intervention group
Group type: EXPERIMENTAL
Intervention: AL (25 mg of allopurinol/kg of body mass)
Number of subjects: 25
Study 23091148 — intervention group
Group type: EXPERIMENTAL
Intervention: AR (AL for 2 wk followed by allopurinol withdrawal over wk 3)
Number of subjects: 25
Study 23091148 — intervention group
Group type: EXPERIMENTAL
Intervention: UAF (AL plus 6.25 g of UA sodium salt/kg of feed)
Number of subjects: 25
Study 23091148 — intervention group
Group type: EXPERIMENTAL
Intervention: UAI (AL plus 120 mg of UA sodium salt injected daily)
Number of subjects: 25
Study 23091148 — intervention group
Group type: EXPERIMENTAL
Intervention: INO (0.6 M inosine/kg of feed)
Number of subjects: 25
Study 23091148 — intervention group
Group type: EXPERIMENTAL
Intervention: INOAL (INO plus 50 mg of allopurinol/kg of body mass)
Number of subjects: 25
Study 23091148 — intervention group
Group type: COMPARATOR
Intervention: Control (0)
Number of subjects: 25
Study 19605567 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of sucrose (37.5 g) 2 h after breakfast and lunch
Number of subjects: 31
Study 19605567 — intervention group
Group type: COMPARATOR
Intervention: Control (water without sucrose)
Number of subjects: 31
Study 19605567 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of sucrose (75 g, equivalent to 2 cans of a soft drink)
Number of subjects: 31
Study 17478225 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tonsillitis
Number of subjects: 0
Study 17478225 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent tonsillitis
Number of subjects: 0
Study 15564986 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure measurement
Number of subjects: 400
Study 15564986 — intervention group
Group type: COMPARATOR
Intervention: Office blood pressure measurement
Number of subjects: 400
Study 10881251 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Number of subjects: 978
Study 10881251 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 978
Study 10881251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 978
Study 8931684 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate 1.8 mg/kg
Number of subjects: 62
Study 8931684 — intervention group
Group type: COMPARATOR
Intervention: Dolasetron mesylate 0.6 mg/kg
Number of subjects: 62
Study 1563056 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (2 ml, 8 mg)
Number of subjects: 30
Study 1563056 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric tetracaine (2 ml, 8 mg)
Number of subjects: 30
Study 3910157 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fractionated pre-operative irradiation (25.5 Gy in 5-7 days)
Number of subjects: 360
Study 3910157 — intervention group
Group type: COMPARATOR
Intervention: Postoperative irradiation (60 Gy in 8 weeks)
Number of subjects: 360
Study 3910157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 360
Study 30833449 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavonoid cocoa beverage
Number of subjects: 40
Study 30833449 — intervention group
Group type: COMPARATOR
Intervention: Low flavonoid cocoa beverage (control)
Number of subjects: 40
Study 28770642 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotional state
Number of subjects: 70
Study 28770642 — intervention group
Group type: COMPARATOR
Intervention: Neutral emotional state
Number of subjects: 70
Study 26583953 — intervention group
Group type: EXPERIMENTAL
Intervention: Slackline training, 6 weeks, 2 times per week
Number of subjects: 24
Study 22664565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ena-Bond-Enamel HFO (n=48)
Number of subjects: 23
Study 22664565 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond-Miris2 (n=48)
Number of subjects: 23
Study 22664565 — intervention group
Group type: COMPARATOR
Intervention: Intact teeth
Number of subjects: 23
Study 22664565 — intervention group
Group type: COMPARATOR
Intervention: Small restorations
Number of subjects: 23
Study 22664565 — intervention group
Group type: COMPARATOR
Intervention: Big restorations
Number of subjects: 23
Study 20736816 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections
Number of subjects: 36
Study 19133087 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot Endo Sealer
Number of subjects: 3
Study 19133087 — intervention group
Group type: COMPARATOR
Intervention: ZOE‐based sealer
Number of subjects: 3
Study 19133087 — intervention group
Group type: COMPARATOR
Intervention: Epoxy resin‐based sealer
Number of subjects: 3
Study 15669614 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuli equated at the cornea
Number of subjects: 20
Study 15669614 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuli corrected for ocular media density differences (equated at the retina)
Number of subjects: 20
Study 12657984 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty Management Intervention provided to the patient only
Number of subjects: 0
Study 12657984 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty Management Intervention supplemented by delivery to the patient and family member
Number of subjects: 0
Study 12657984 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 12657984 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty Management Intervention
Number of subjects: 0
Study 10847307 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 2967
Study 10847307 — intervention group
Group type: COMPARATOR
Intervention: Other antipsychotic drugs (Control)
Number of subjects: 2967
Study 8838441 — intervention group
Group type: EXPERIMENTAL
Intervention: 311C90 (1-50 mg, single oral doses)
Number of subjects: 12
Study 1289588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (CFPZ) at a mean dose of 8.4 mg/kg, administered 3-4 times daily for an average of 6 days.
Number of subjects: 73
Study 1289588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (CFPZ) at a daily dose of 30.1-45.0 mg/kg.
Number of subjects: 73
Study 1289588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (CFPZ) against 53 isolates of Staphylococcus aureus.
Number of subjects: 73
Study 1289588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (CFPZ) against Methicillin-resistant S. aureus (MRSA).
Number of subjects: 73
Study 1289588 — intervention group
Group type: COMPARATOR
Intervention: Cefprozil (CFPZ) compared to other antibiotics (CEX, CCL, ABPC, DMPPC, MCIPC).
Number of subjects: 73
Study 3885985 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil (400 mg/day for 10 weeks)
Number of subjects: 0
Study 3885985 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 3885985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30353579 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% DBP
Number of subjects: 120
Study 30353579 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% DBP
Number of subjects: 120
Study 30353579 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% DBP
Number of subjects: 120
Study 30353579 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% DBP
Number of subjects: 120
Study 30353579 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% DBP
Number of subjects: 120
Study 30353579 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP (various levels)
Number of subjects: 120
Study 30353579 — intervention group
Group type: COMPARATOR
Intervention: Control (0% DBP)
Number of subjects: 120
Study 30173287 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry juice (MTCJ) supplementation
Number of subjects: 11
Study 30173287 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study 26700585 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 30
Study 26700585 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors
Number of subjects: 30
Study 26700585 — intervention group
Group type: EXPERIMENTAL
Intervention: TZDs
Number of subjects: 30
Study 26700585 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 analogues
Number of subjects: 30
Study 26700585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25055812 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Trial Agreement introduced
Number of subjects: 39
Study 25055812 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of site investigators and research culture
Number of subjects: 39
Study 25055812 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in approval of the new Clinical Trial Agreement
Number of subjects: 39
Study 20121112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m² and cetuximab 400 mg/m² loading dose followed by 250 mg/m² for 6 weeks with pelvic RT (DL 1)
Number of subjects: 54
Study 20121112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m² and cetuximab 400 mg/m² loading dose followed by 250 mg/m² for 6 weeks with pelvic RT (DL 2)
Number of subjects: 54
Study 20121112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m² and cetuximab with extended field radiation therapy (EFRT) (DL 1)
Number of subjects: 54
Study 20121112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and cetuximab with EFRT (feasibility phase)
Number of subjects: 54
Study 20473913 — intervention group
Group type: EXPERIMENTAL
Intervention: Catumaxomab (10, 20, 50 and 150 mug i.p. infusion on Days 0, 3, 7 and 10)
Number of subjects: 258
Study 20473913 — intervention group
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Number of subjects: 258
Study 20473913 — intervention group
Group type: COMPARATOR
Intervention: Control (paracentesis alone)
Number of subjects: 258
Study 18556337 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin administration
Number of subjects: 708
Study 18556337 — intervention group
Group type: EXPERIMENTAL
Intervention: DQB*0302 allele presence
Number of subjects: 708
Study 18556337 — intervention group
Group type: EXPERIMENTAL
Intervention: DQB*0301 allele presence
Number of subjects: 708
Study 18556337 — intervention group
Group type: EXPERIMENTAL
Intervention: INS-23 genotype
Number of subjects: 708
Study 19687359 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg
Number of subjects: 54
Study 19687359 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 54
Study 19687359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 14759614 — intervention group
Group type: EXPERIMENTAL
Intervention: EE20/LNG100
Number of subjects: 12
Study 14759614 — intervention group
Group type: EXPERIMENTAL
Intervention: EE30/LNG150
Number of subjects: 12
Study 11334895 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 16
Study 11334895 — intervention group
Group type: COMPARATOR
Intervention: desogestrel/EE COC
Number of subjects: 16
Study 9220209 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 20 mg
Number of subjects: 217
Study 9220209 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 217
Study 9220209 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 217
Study 9220209 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 217
Study 9220209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 8501477 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical experiment abstract
Number of subjects: 0
Study 8501477 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-control study abstract
Number of subjects: 0
Study 8501477 — intervention group
Group type: COMPARATOR
Intervention: Placebo abstract
Number of subjects: 0
Study 3792435 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 5 mg/kg
Number of subjects: 145
Study 3792435 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 10 mg/kg
Number of subjects: 145
Study 3792435 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 15 mg/kg
Number of subjects: 145
Study 12365879 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-based intervention
Number of subjects: 59
Study 12365879 — intervention group
Group type: COMPARATOR
Intervention: Specific preventive intervention (low-dose risperidone therapy, mean dosage 1.3 mg/d, and cognitive behavior therapy)
Number of subjects: 59
Study 31567716 — intervention group
Group type: COMPARATOR
Intervention: Bracing (orthosis)
Number of subjects: 119
Study 31567716 — intervention group
Group type: COMPARATOR
Intervention: No bracing (no orthosis)
Number of subjects: 119
Study 29938452 — intervention group
Group type: EXPERIMENTAL
Intervention: UI05MSP015CT (15 mg once a day)
Number of subjects: 138
Study 29938452 — intervention group
Group type: COMPARATOR
Intervention: Mosapride (5 mg three times a day, control group)
Number of subjects: 138
Study 26360545 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy (CCBT)
Number of subjects: 199
Study 26360545 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 199
Study 24577019 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexmedetomidine (0.2 μg/kg/h titrated to 0.7 μg/kg/h)
Number of subjects: 33
Study 24577019 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexmedetomidine
Number of subjects: 33
Study 24577019 — intervention group
Group type: COMPARATOR
Intervention: Use of midazolam
Number of subjects: 33